Systemic Glucocorticoid Therapy in SLE

Dubois' Lupus Erythematosus and Related Syndromes: Eighth Edition

Volumn , Issue , 2013, Pages 591-600

  Kirou, Kyriakos A ^a,b   Boumpas, Dimitrios T ^c,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942891818     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1893-5.00048-0     Document Type: Chapter

References (95)

1. Rauchhaus U, Schwaiger FW, Panzner S Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment. Arthritis Res Ther 2009, 11(6):R190.
2. Anderson R, Franch A, Castell M, et al. Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Res Ther 2010, 12(4):R147.
3. Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 2010, 69(7):1275-1280.
4. Kvien TK, Fjeld E, Slatkowsky-Christensen B, et al. Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis. Ann Rheum Dis 2008, 67(7):942-948.
5. Rider CF, King EM, Holden NS, et al. Inflammatory stimuli inhibit glucocorticoid-dependent transactivation in human pulmonary epithelial cells: rescue by long-acting beta2-adrenoceptor agonists. J Pharmacol Exp Ther 2011, 338(3):860-869.
6. Newton RR, Leigh R, Giembycz MA Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases. Pharmacol Ther 2010, 125(2):286-327.
7. Rhen T, Cidlowski JA Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005, 353(16):1711-1723.
8. Perretti M, D'Acquisto F Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009, 9(1):62-70.
9. Baschant U, Tuckermann J The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol 2010, 120(2-3):69-75.
10. Löwenberg M, Verhaar AP, Bilderbeek J, et al. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep 2006, 7(10):1023-1029.
11. Zhou J, Li M, Sheng CQ, et al. A novel strategy for development of glucocorticoids through non-genomic mechanism. Cell Mol Life Sci 2011, 68(8):1405-1414.
12. Song IH, Buttgereit F Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol 2006, 246(1-2):142-146.
13. Buttgereit F, Burmester GR, Straub RH, et al. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011, 63(1):1-9.
14. Lawrence T, Gilroy DW Chronic inflammation: a failure of resolution?. Int J Exp Pathol 2007, 88(2):85-94.
15. Perretti M, Ahluwalia A The microcirculation and inflammation: site of action for glucocorticoids. Microcirculation 2000, 7(3):147-161.
16. Barnes PJ Glucocorticosteroids: current and future directions. Br J Pharmacol 2011, 163(1):29-43.
17. Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010, 465(7300):937-941.
18. Tsujimura S, Saito K, Nakayamada S, et al. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52(6):1676-1683.
19. Sergent JS, Lockshin MD, Klempner MS, et al. Central nervous system disease in systemic lupus erythematosus. Therapy and prognosis. Am J Med 1975, 58(5):644-654.
20. Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002, 61(8):718-722.
21. Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993, 119(12):1198-1208.
22. Hoc Ad Working Group on Steroid-Sparing Criteria in Lupus: Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting. Arthritis Rheum 2004, 50(11):3427-3431.
23. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995, 345(8965):1595-1599.
24. Tseng CE, Buyon JP, Kim M, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54(11):3623-3632.
25. Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996, 125(7):549-557.
26. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001, 135(4):248-257.
27. Parker BJ, Bruce LN High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 2007, 16(6):387-393.
28. Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005, 64(4):620-625.
29. Chatham WW, Kimberly RP Treatment of lupus with corticosteroids. Lupus 2001, 10(3):140-147.
30. Medina F, Ayala A, Jara LJ, et al. Acute abdomen in systemic lupus erythematosus: the importance of early laparotomy. Am J Med 1997, 103(2):100-105.
31. Fessler BJ, Boumpas DT Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. Rheum Dis Clin North Am 1995, 21(1):81-98.
32. Boumpas DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992, 340(8822):741-745.
33. Fox DA, McCune WJ Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 1994, 20(1):265-299.
34. Frediani B, Falsetti P, Bisogno S, et al. Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J Rheumatol 2004, 31(6):1083-1087.
35. Wada K, Yamada N, Suzuki H, et al. Recurrent cases of corticosteroid-induced mood disorder: clinical characteristics and treatment. J Clin Psychiatry 2000, 61(4):261-267.
36. Badsha H, Kong KO, Lian TY, et al. Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. Lupus 2002, 11(8):508-513.
37. Badsha H, Edwards CJ Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003, 32(6):370-377.
38. Danowski A, Magder L, Petri M Flares in Lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. J Rheumatol 2006, 33(1):57-60.
39. Friedman DM, Kim MY, Copel JA, et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009, 103(8):1102-1106.
40. Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007, 197(6):585e1-585e7.
41. Peltoniemi OM, Kari MA, Hallman M Repeated antenatal corticosteroid treatment: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2011, 90(7):719-727.
42. French NP, Hagan R, Evans SF, et al. Repeated antenatal corticosteroids: effects on cerebral palsy and childhood behavior. Am J Obstet Gynecol 2004, 190(3):588-595.
43. Temprano KK, Bandlamudi R, Moore TL Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005, 35(2):112-121.
44. Clowse ME, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006, 54(11):3640-3647.
45. Marik PE, Varon J Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg 2008, 143(12):1222-1226.
46. Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007, 157(1):142-148.
47. McDonough AK, Curtis JR, Saag KG The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008, 20(2):131-137.
48. Fardet L, Cabane J, Kettaneh A, et al. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology 2007, 46(7):1102-1106.
49. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003, 30(9):1955-1959.
50. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000, 43(8):1801-1808.
51. Weinstein RS Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011, 365(1):62-70.
52. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010, 62(11):1515-1526.
53. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001, 44(1):202-211.
54. Reid DM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. Journal of bone and mineral research. J Bone Miner Res 2000, 15(6):1006-1013.
55. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373(9671):1253-1263.
56. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357(20):2028-2039.
57. Nagasawa K, Tada Y, Koarada S, et al. Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 2005, 14(5):385-390.
58. Nakamura J, Harada Y, Oinuma K, et al. Spontaneous repair of asymptomatic osteonecrosis associated with corticosteroid therapy in systemic lupus erythematosus: 10-year minimum follow-up with MRI. Lupus 2010, 19(11):1307-1314.
59. Nakamura J, Saisu T, Yamashita K, et al. Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum 2010, 62(2):609-615.
60. Agarwala S, Shah S, Joshi VR The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years. J Bone Joint Surg Br 2009, 91(8):1013-1018.
61. Skamra C, Ramsey-Goldman R Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumtol 2010, 5(1):75-100.
62. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349(25):2399-2406.
63. Karp I, Abrahamowicz M, Fortin PR, et al. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?. Arthritis Rheum 2008, 59(2):169-175.
64. Hadoke PW, Iqbal J, Walker BR Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol 2009, 156(5):689-712.
65. Calvo-Alén J, Toloza SM, Fernández M, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005, 52(7):2060-2068.
66. Cherian J, Duculan R, Amigues I, et al. A 26-year-old white man with a systemic lupus erythematosus flare and acute multiorgan ischemia: vasculitis or thrombosis?. Arthritis Care Res 2011, 63(5):766-774.
67. Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008, 35(3):387-393.
68. Dixon WG, Kezouh A, Bernatsky S, et al. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 2011, 70(6):956-960.
69. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301(7):737-744.
70. Lionakis MS, Kontoyiannis DP Glucocorticoids and invasive fungal infections. Lancet 2003, 362(9398):1828-1838.
71. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006, 55(1):19-26.
72. Weng CT, Lee NY, Liu MF, et al. A retrospective study of catastrophic invasive fungal infections in patients with systemic lupus erythematosus from southern Taiwan. Lupus 2010, 19(10):1204-1209.
73. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity 38(7):473-485, 2005.
74. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010, 69(7):1269-1274.
75. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007, 66(12):1560-1567.
76. Coutinho AE, Chapman KE The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011, 335(1):2-13.
77. Barnes PJ, Adcock IM Glucocorticoid resistance in inflammatory diseases. Lancet 2009, 373(9678):1905-1917.
78. Heasman SJ, Giles KM, Ward C, et al. Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: implications for the resolution of inflammation. J Endocrinol 2003, 178(1):29-36.
79. Abramson SB, Dobro J, Eberle MA, et al. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med 1991, 114(11):941-947.
80. Flammer JR, Dobrovolna J, Kennedy MA, et al. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol 2010, 30(19):4564-4574.
81. Vallelian F, Schaer CA, Kaempfer T, et al. Glucocorticoid treatment skews human monocyte differentiation into a hemoglobin-clearance phenotype with enhanced heme-iron recycling and antioxidant capacity. Blood 2010, 116(24):5347-5356.
82. Ehrchen J, Steinmöller L, Barczyk K, et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 2007, 109(3):1265-1274.
83. McColl A, Bournazos S, Franz S, et al. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J Immunol 2009, 183(3):2167-2175.
84. Barczyk K, Ehrchen J, Tenbrock K, et al. Glucocorticoids promote survival of anti-inflammatory macrophages via stimulation of adenosine receptor A3. Blood 2010, 116(3):446-455.
85. Abe M, Thomson AW Dexamethasone preferentially suppresses plasmacytoid dendritic cell differentiation and enhances their apoptotic death. Clin Immunol 2006, 118(2-3):300-306.
86. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197(6):711-723.
87. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52(5):1491-1503.
88. Wüst S, van den Brandt J, Tischner D, et al. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol 2008, 180(12):8434-8443.
89. Harr MW, Rong Y, Bootman MD, et al. Glucocorticoid-mediated inhibition of Lck modulates the pattern of T cell receptor-induced calcium signals by down-regulating inositol 1,4,5-trisphosphate receptors. J Biol Chem 2009, 284(46):31860-31871.
90. Zhang S, Shen Z, Hu G, et al. Effects of endogenous glucocorticoids on allergic inflammation and T(H)1/T(H)2 balance in airway allergic disease. Ann Allergy Asthma Immunol 2009, 103(6):525-534.
91. Liberman AC, Druker J, Refojo D, et al. Glucocorticoids inhibit GATA-3 phosphorylation and activity in T cells. FASEB J 2009, 23(5):1558-1571.
92. Deng J, Younge BR, Olshen RA, et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010, 121(7):906-915.
93. Suárez A, López P, Gómez J, et al. Enrichment of CD4+ CD25 high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis 2006, 65(11):1512-1517.
94. Zhu XJ, Shi Y, Sun JZ, et al. High-dose dexamethasone inhibits BAFF expression in patients with immune thrombocytopenia. J Clin Immunol 2009, 29(5):603-610.
95. Surjit M, Ganti KP, Mukherji A, et al. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 2011, 145(2):224-241.